Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of COVID-HIGIV in Healthy Adults
NCT04661839Phase 1Completed
- Sponsor
- Emergent BioSolutions
- Start
- Dec 2020
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of anti-COVID-19 immune globulin in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Emergent BioSolutions. Primary endpoints: Subjects With Adverse Events (AEs) up to 3 Days Post-dosing, Subjects With Adverse Events That Led to Discontinuation or Temporary Suspension of IV Infusion at 2.5 hours and 8 more. Started Dec 2020; status: completed.
02
Drugs
anti-COVID-19 immune globulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04661839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661839.